Kopran Limited (KOPRAN) — Financial Results | 7 August 2026

Kopran Limited reported Q1 FY2026-27 revenue of [amount not verified], up sharply from [amount not verified] in Q1 FY2025-26, driven by strong API and formulation sales. EBITDA rose to [amount not verified] from ₹0.39 crores YoY, with EBITDA margin expanding to 10.31%. Net profit reached [amount not verified], while finance costs remained stable at [amount not verified]. The company highlighted growth in anti-diabetic and antibiotic APIs, increased export sales, and strategic focus on R&D and regulatory compliance. Forward-looking statements indicate continued investment in capacity and self-reliance. Investors should monitor execution of growth initiatives amid regulatory and market risks.